A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function

NCT06916078

Status	RECRUITING
Phase	Phase 1
Sponsor	Eli Lilly and Company
Enrollment	33 participants

Key Eligibility Criteria

Inclusion (4)

- Have a body weight of 55 kilogram (kg) or more and body mass index within the range 19.0 to 42.0 kilogram per square meter (kg/m^2)
- Healthy participants with clinically normal hepatic function
- For Participants with Mild to Severe Hepatic Impairment in Groups 2 through 4:
- Participants with hepatic impairment classified as Child-Pugh score A, B, or C (mild, moderate, or severe impairment). Diagnosis of chronic hepatic impairment of greater than 6 months, per physician diagnosis and standard-of-care practice

Exclusion (7)

- Have significant history of, or current, cardiovascular (CV), respiratory, hepatic (hepatic applies to Group 1 only), renal, gastrointestinal, endocrine, hematological, or neurological disorders
- Have severe atopy or a history of clinically significant multiple or severe drug allergies
- Have known allergies to lepodisiran, related compounds, or any components of the formulation
- Have a history of, or current, psychiatric disorders
- Have had any malignancy within the past 5 years

... and 2 more (see full listing online)

Locations (4 total)

Clinical Pharmacology of Miami, Miami, Florida, United States
Orlando Clinical Research Center, Orlando, Florida, United States
American Research Corporation at Texas Liver Institute, San Antonio, Texas, United States
... and 1 more locations